A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer

Clinical trial NCT05054374 · COMPLETED

Trial details

NCT number: NCT05054374
Sponsor: Memorial Sloan Kettering Cancer Center
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Breast Cancer Breast Cancer Stage IV HER2-negative Breast Cancer Solid Carcinoma MEK1 Gene Mutation MEK2 Gene Mutation Metastatic Breast Cancer

Start date: 2021-09-14
Primary completion: 2023-10-26
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.